CG Oncology (CGON) Non Operating Income (2023 - 2026)

CG Oncology's Non Operating Income history runs 4 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• Quarterly Non Operating Income fell 20.19% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (down 2.18% YoY) and the FY2025 annual result came in at $29.8 million, up 11.84% from the prior year.
• Non Operating Income was $6.2 million for Q1 2026 at CG Oncology, down from $7.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at $7.9 million in Q3 2024 and bottomed at $713000.0 in Q2 2023.
• A 4-year average of $5.3 million and a median of $6.3 million in 2024 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2024 — Non Operating Income jumped 874.89% — and 2026, when it declined 20.19%.
• CG Oncology's Non Operating Income stood at $2.8 million in 2023, then soared by 123.25% to $6.3 million in 2024, then rose by 18.24% to $7.4 million in 2025, then declined by 16.29% to $6.2 million in 2026.
• Business Quant data shows CGON's Non Operating Income at $6.2 million in Q1 2026, $7.4 million in Q4 2025, and $7.3 million in Q3 2025.